Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 80

1.

Lamivudine in the last 4 weeks of pregnancy to prevent perinatal transmission in highly viremic chronic hepatitis B patients.

van Nunen AB, de Man RA, Heijtink RA, Niesters HG, Schalm SW.

J Hepatol. 2000 Jun;32(6):1040-1. No abstract available.

PMID:
10898328
2.

Antenatal lamivudine to reduce perinatal hepatitis B transmission: a cost-effectiveness analysis.

Nayeri UA, Werner EF, Han CS, Pettker CM, Funai EF, Thung SF.

Am J Obstet Gynecol. 2012 Sep;207(3):231.e1-7. doi: 10.1016/j.ajog.2012.06.001. Epub 2012 Jun 11.

PMID:
22939730
3.

Lamivudine for chronic hepatitis B.

Leung N.

Expert Rev Anti Infect Ther. 2004 Apr;2(2):173-80. Review.

PMID:
15482184
4.

Lamivudine treatment during pregnancy to prevent perinatal transmission of hepatitis B virus infection.

van Zonneveld M, van Nunen AB, Niesters HG, de Man RA, Schalm SW, Janssen HL.

J Viral Hepat. 2003 Jul;10(4):294-7.

PMID:
12823596
5.

Management of hepatitis B in pregnancy: weighing the options.

Tran TT.

Cleve Clin J Med. 2009 May;76 Suppl 3:S25-9. doi: 10.3949/ccjm.76.s3.06.

PMID:
19465706
6.

Pre-emptive use of lamivudine in bone marrow transplantation with chronic hepatitis B virus infection.

Deschênes M, Laneuville P.

Hepatology. 2004 Mar;39(3):867; author reply 867-8. No abstract available.

PMID:
14999714
7.

Lamivudine in late pregnancy to prevent perinatal transmission of hepatitis B virus infection: a multicentre, randomized, double-blind, placebo-controlled study.

Xu WM, Cui YT, Wang L, Yang H, Liang ZQ, Li XM, Zhang SL, Qiao FY, Campbell F, Chang CN, Gardner S, Atkins M.

J Viral Hepat. 2009 Feb;16(2):94-103. doi: 10.1111/j.1365-2893.2008.01056.x. Epub 2008 Oct 8.

PMID:
19175878
8.

A multi-center open study to determine the effect of lamivudine on HBV DNA clearance and to assess the safety of the regimen in patients with chronic hepatitis B infection.

Mazur W, Król F, Cianciara J, Nazzal K, Gładysz A, Juszczyk J, Bolewska B, Adamek J, Czajka B, Swietek K, Kryczka W, Gonciarz Z.

Med Sci Monit. 2002 Apr;8(4):CR257-62.

PMID:
11951067
9.

Lamivudine therapy for chronic hepatitis B virus infection and pregnancy: a case report.

Tomasiewicz K, Modrzewska R, Krawczuk G, Lyczak A.

Int J Infect Dis. 2001;5(2):115-6. No abstract available.

10.

Lactic acid levels in children perinatally treated with antiretroviral agents to prevent HIV transmission.

Giaquinto C, De Romeo A, Giacomet V, Rampon O, Ruga E, Burlina A, De Rossi A, Sturkenboom M, D'Elia R.

AIDS. 2001 May 25;15(8):1074-5. No abstract available.

PMID:
11399997
11.

Liver transplantation for patients with lamivudine-resistant HBV: what is the optimal prophylactic strategy?

Lok AS.

Liver Transpl. 2005 May;11(5):490-3. Review. No abstract available.

12.

Efficacy and tolerability of long-term therapy using high lamivudine doses for the treatment of chronic hepatitis B.

Da Silva LC, Pinho JR, Sitnik R, Da Fonseca LE, Carrilho FJ.

J Gastroenterol. 2001 Jul;36(7):476-85.

PMID:
11480792
13.

Lamivudine plus interleukin-12 combination therapy in chronic hepatitis B: antiviral and immunological activity.

Rigopoulou EI, Suri D, Chokshi S, Mullerova I, Rice S, Tedder RS, Williams R, Naoumov NV.

Hepatology. 2005 Nov;42(5):1028-36.

PMID:
16250037
14.

In vivo immunization by vaccine therapy following virus suppression by lamivudine: a novel approach for treating patients with chronic hepatitis B.

Horiike N, Fazle Akbar SM, Michitaka K, Joukou K, Yamamoto K, Kojima N, Hiasa Y, Abe M, Onji M.

J Clin Virol. 2005 Feb;32(2):156-61.

PMID:
15653419
15.

Favorable efficacy of long-term lamivudine therapy in patients with chronic hepatitis B: an 8-year follow-up study.

Akuta N, Suzuki F, Suzuki Y, Sezaki H, Hosaka T, Someya T, Kobayashi M, Saitoh S, Arase Y, Ikeda K, Kobayashi M, Kumada H.

J Med Virol. 2005 Apr;75(4):491-8.

PMID:
15714490
16.

Chemoprevention of hepatocellular carcinoma in chronic hepatitis B with lamivudine?

Lim LY, Kowdley KV.

Gastroenterology. 2005 Dec;129(6):2120-2; discussion 2122. No abstract available.

PMID:
16344085
17.
18.

Lamivudine treatment in HBeAg-negative chronic hepatitis B patients with low level viraemia.

Bozkaya H, Yurdaydin C, Idilman R, Tüzün A, Cinar K, Erkan O, Bozdayi AM, Erden E, Uzun Y, Cetinkaya H, Uzunalimoglu O.

Antivir Ther. 2005;10(2):319-25.

PMID:
15865226
19.

Prophylactic lamivudine prevents hepatitis B reactivation in chemotherapy patients.

Lim LL, Wai CT, Lee YM, Kong HL, Lim R, Koay E, Lim SG.

Aliment Pharmacol Ther. 2002 Nov;16(11):1939-44.

20.

Factors influencing outcome of lamivudine in anti-HBe-positive chronic hepatitis B.

Ascione A, Ascione T, Lanza AG, Utech W, Di Costanzo GG, Macri M.

Hepatogastroenterology. 2006 Nov-Dec;53(72):919-23.

PMID:
17153453

Supplemental Content

Support Center